Overview

A Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Type 1 Diabetes Subjects

Status:
Completed
Trial end date:
2018-05-25
Target enrollment:
Participant gender:
Summary
The objective of the trial is to demonstrate superiority of dasiglucagon compared to placebo following a single subcutaneous dose administered to subjects with type 1 diabetes mellitus (T1DM) with insulin-induced hypoglycemia. Additionally to compare the glycemic response observed after administration dasiglucagon with that of GlucaGen®.
Phase:
Phase 3
Details
Lead Sponsor:
Zealand Pharma
Treatments:
Glucagon